Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01234051
Other study ID # KSWOG 2010-1
Secondary ID
Status Recruiting
Phase Phase 2
First received October 28, 2010
Last updated December 9, 2011
Start date November 2010
Est. completion date December 2013

Study information

Verified date November 2010
Source Korean South West Oncology Group
Contact Eun Ki Song
Phone +82-63-250-1245
Email eksong@jbnu.ac.kr
Is FDA regulated No
Health authority Republic of Korea: Korea Food and Drug Administration
Study type Interventional

Clinical Trial Summary

1. Goals

- The primary goal of this phase II trial is to:

evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy

Secondary goals are to:evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population

2. Design

The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon.22


Recruitment information / eligibility

Status Recruiting
Enrollment 53
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically

2. Unresectable locally advanced, metastatic, or recurrent biliary tract cancer

3. Patients must be = 18 years old of age

4. ECOG performance status = 2 (see Appendix C)

5. At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (see Appendix D)

6. Estimated life expectancy of more than 3 months

7. Adequate bone marrow function (absolute neutrophil count [ANC] = 1,500/µL, hemoglobin = 9.0 g/dL [correction by transfusion is acceptable], and platelets = 100,000/µL)

8. Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN])

9. Adequate liver function (serum total bilirubin < 3xULN; serum transaminases levels < 5xUNL)

10. Provision of fully informed consent prior to any study specific procedures

Exclusion Criteria:

1. Other tumor type than adenocarcinoma

2. Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy)

3. Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for =5 years)

4. Patients who received radiotherapy on target lesion within 6 months prior to study treatment

5. Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases

6. Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery

7. Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception

8. Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (= Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study

9. Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Docetaxel, Oxaliplatin
1. Treatment Schedule 1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required. 1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days.

Locations

Country Name City State
Korea, Republic of Eun Ki Song Chonbuk

Sponsors (1)

Lead Sponsor Collaborator
Korean South West Oncology Group

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate 2years No
Secondary Treatment-related toxicities Number and proportion of patients with adverse events according to the NCI-CTCAE (v 4.0) as a measure of treatment-related toxicities 2 years Yes
Secondary Progression free survival Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves.
The median PFS and OS will be used for measure.
2 years Yes
Secondary Overall survival Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves.
The median PFS and OS will be used for measure.
2 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Withdrawn NCT03110510 - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00380588 - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase 2
Terminated NCT00090025 - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Phase 3
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT05998447 - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer Phase 2
Recruiting NCT03718897 - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting NCT05056116 - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer N/A
Recruiting NCT04692051 - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Terminated NCT04057365 - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Recruiting NCT04584996 - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed NCT02579616 - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Phase 2
Recruiting NCT05052099 - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT01494363 - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Phase 2
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Terminated NCT00630890 - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition